BeeBet(ビーベット)日本で安全なスポーツベット＆オンカジ体験

MENU Company Company Back Company Message from Top Management Our Founding Spirit Brand Statement Our Story Our History of Value Creation Vision and Strategy Framework Group Vision Long-Term Management Strategy Management Policy Medium-Term Management Plan Corporate Information and Business Sites Business Overview Introduction of Executives Corporate Governance Group Companies Procurement Policy Corporate Policy over Internal Control Integrated Report Products and Technology Products Back Products Search by Application Mobility Architectural Materials Infrastructure / General Industry Electronics Semiconductors Energy Daily commodities, Food industry Life Science Search by Business Category Architectural Glass Automotive Display Electronic Materials Essential Chemicals Performance Chemicals Life Science Ceramics New Business Search by Name Search by Keyword Technology and Innovation back Technology and Innovation A Message from the Chief Technology Officer Technology Development Strategy Intellectual Property Strategy R&D Structure Core Technologies Technology Highlights Mobility Electronics Life Science AGC Yokohama Technical Center AGC OPEN SQUARE “AO” Overview Facility Guide Access Collaboration Research Collaboration System R&D Library Measures to Prevent Misconduct in Research and Properly Manage Public Research Funds Sustainability Sustainability Back Sustainability Protecting the Global Environment and Utilizing Resources Supporting the Evolution of Cities and Mobility Realizing Longevity Society Where People Can Live in Good Health Creating a Healthy and Secure Society through Connections Generating New Value from Fair and Safe Workplaces Message from the President and CEO The AGC Group’s Sustainability Management Sustainability Promotion System Download Report Site Reports External Evaluations GRI Standards Index Sustainability-related policies, criteria, and guidelines AGC Group Code of Conduct/Compliance Help Lines Investors Investors Back Investors Management Information To Our Shareholders Vision and Strategy Framework Business Risks Disclosure Policy Financial Highlights IR News IR Library Company Overview Presentations of Financial Results Presentations of Business Briefings Financial Results Financial Review AGC Review (Newsletter for Shareholders) ESG Information Sustainability Corporate Governance Integrated Report Stock and Bond Information Stock Information Corporate Bond and Rating Information Dividend Information Analyst Coverage General Meeting of Shareholders Methods for Various Stock Procedures Electronic Public Notice Articles of Incorporation Stock Price Contact Us FAQ IR Email News Support Information IR Calendar Cautionary Statement IR Site Map Careers News Contact EN JP CN Search March 17, 2020Management Download PDF Print AGC Decides to Launch Voluntary Tender Offer for Shares of Molmed AGC Inc., (Headquarters: Tokyo; President & CEO: Takuya Shimamura)　has decided to launch a voluntary tender offer (“VTO”) to acquire all ordinary shares of Molecular Medicine S.p.A. (“Molmed”) a company with shares listed on the Italian Stock Exchange (Milan) pursuant to article 102, first paragraph, of the Italy Legislative Decree No. 58 of 24 February 1998 and related regulations. Molmed is a clinical stage biotechnology company focused on research, development, manufacturing and clinical validation of gene & cell therapies, and offers GMP services for the development and manufacturing of gene & cell therapies for third parties and/or in partnership at its authorized facilities (“CDMO Services”*1). The VTO aims to obtain all of the issued shares of Molmed (463,450,672) at 0.518 Euros/share, amounting to 240 Million Euros if all of the shares are successfully acquired, and the subsequent delisting of the Issuer from the Italian Stock Exchange. This VTO is subject to certain conditions (e.g. the acceptances of the VTO of a number of shares representing not lower than 66.7% of the entire share capital), and is more fully described in the notice to the market issued in accordance with Italian law. Further details of the VTO will be contained in the offer document which will be published in the next few weeks. This VTO is backed by Molmed’s largest shareholder, Fininvest S.p.A. (holding 23.13% of the shares of Molmed) which has irrevocably undertaken to bring all of its Molmed shares in the VTO, and we expect endorsement from Molmed management as well. Gene & cell therapy is an innovative therapeutic method, that aim to treat diseases that do not have adequate treatments to date. Approximately 1000 clinical trials are underway worldwide, and the market is expected to grow at a rapid rate. Molmed has strength especially in vectors and cells manufacturing backed by its robust production platform, also providing third party GMP manufacturing services of engineered cells and viral vectors for various companies from large biopharmaceuticals to biotech companies. Under its AGC plus management policy, the AGC Group has made a commitment to position its life-sciences related business, including the biopharmaceutical CDMO business, as one of its strategic initiatives, aiming at sales above the 100-billion-yen range by 2025. To date, AGC has actively invested in its small molecule pharmaceutical CDMO business and its biopharmaceutical CDMO business, and has established a stable presence in the industry. Through the acquisition of Molmed, AGC will enter into the innovative gene & cell therapy field to expand its CDMO offering to the area where there is a strong imbalance between demand and supply of specific skills and production capacity worldwide, and to better serve the pharmaceutical companies, its patients and society. Notes:*1)　CDMO: Contract Development & Manufacturing Organization REFERENCE ■Information on Molmed Established 1996 Located Milan, Italy Number of employees App. 220 Revenue 36.3 Million Euros (2019) Business Arena Gene & Cell therapy Discovery, R&D, Manufacturing, Clinical Validation, Third Party GMP Services. Issued shares 463,450,672 Website https://www.molmed.com/en/node/1 ■Where Molmed fits into AGC’s Business MEDIA INQUIRIES Kazumi Tamaki, General Manager, Corporate Communications & Investor Relations DivisionAGC Inc. Contact: Yuki Kitano TEL: +81-3-3218-5603 E-mail: [email protected] Share News Index HomeNewsAGC Decides to Launch Voluntary Tender Offer for Shares of Molmed Check in AGC Site Map About Social Media Contact About This Site Privacy Policy ©AGC Inc.